CN
93-92-5
应用筛选条件
关键词:'93-92-5'
显示 1-30 共 434 条结果 关于 "93-92-5" 范围 技术文档
The Effective Use of Protein Kinase Inhibitors
96 72 71 79 93 106
56 103 13 5 2 62 39 19 92 88 40 92 98 55 57 93 94 51 74 88 59 14
96 85 102 101 76 50 58 77 87 76
The Effective Use of Protein Kinase Inhibitors
96 72 71 79 93 106
56 103 13 5 2 62 39 19 92 88 40 92 98 55 57 93 94 51 74 88 59 14
96 85 102 101 76 50 58 77 87 76
High throughput sample preparation for the quantitation of drug compounds in serum samples
Deviation
Digoxin 97% 7% 91% 3%
Propranolol 94% 5% 91% 4%
Taxol 93% 5% 93% 4%
Testosterone 101% 5% 93% 4%
Verapamil 95% 6% 96% 5%
Warfarin 92% 4% 87% 4%
Development of Multiplex Immunoassay Panels for Simultaneous Quantification of Bone Metabolism Markers using Luminex xMAP Technology
%):
1A 1B 2A 2B
RANKL — — 119 78
OPG 95 90 — —
Insulin 92 101 92 91
Leptin 87 93 93 93
ACTH 117 92 115 85
IL-6 86 87 89 90
TNFα 122 92 133 93
Osteocalcin — 99 — 97
PRECISION:
Intra-assay <4%
Inter-assay
Product Information Sheet - 80476
Page 3 of 5
Figure 2: Product Drawing
DUO +34 deg C
Run-Time acceleration with temp
Scalability of Mobius®Single-Use Bioreactors
80
90
100
50 L 200 L 1000 L 2000 L
Model Prediction Emperical Data
90
91
92
93
94
95
96
97
98
99
Data Sheet - H161
METHYLENEDIOXYAMPHETAMINE
(±)-N-HYDROXY MDA
>93% purity
CNS stimulant; hallucinogen.
Mol. Formula: C10H13NO3
Mol. Wt.: 195.22 (anhyd.)
m.p.: 92-93°C
CAS Registry No.: 114562-59-3
Chemical
RABBIT ANTI-VESICULAR MONOAMINE TRANSPORTER 2 AFFINITY PURIFIED
PNAS (1995) 92:8773-8777.
3) J. Cell Biol. (1994) 127:1419-1433.
4) FEBS Lett. (1993) 318:325-330; J Neurochem. (1993) 61:2314-2317.
5) J. Neurosci. (1996) 16:4135-4145.
6) PNAS (1996) 93:5166-5171
Dental Application Brochure
Inhibitor 150-76-5
2, 6-Di-tert-butyl-4-methylphenol Inhibitor 128-37-0
Platinum (0)-1, 3-divinyl-1, 1, 3,
3-tetramethyldisiloxane
complex solution
Catalyst;
hydrosilylation
68478-92-2
Triphenylphosphine
MILLIPLEX®MAP Human Myokine Panel is an optimized quantitative immunoassay that simultaneously measures 15 novel muscle-secreted factors
84 100 82 106
+std 4 92 104 113 77 90 101 105 128 93 115 114 77 130 92 109
+std 5 85 94 135 72 75 101 99 150 90 99 97 72 155 90 156
Data Sheet - SAB4200884
Hassett DJ., J Bacteriol., 178, 7322–5 (1996).
3. Mulcahy LR., et al., Microb Ecol., 68, (2014).
4. Smith EE., et al., P Natl Acad Sci USA., 103,
8487–92 (2006).
5. Sadikot RT., et al., Am J Respir
Data Sheet - SAB4200866
Hassett DJ., J Bacteriol., 178: 7322–5 (1996).
3. Mulcahy LR., et al., Microb Ecol., 68: (2014).
4. Smith EE., et al., P Natl Acad Sci USA., 103:
8487–92 (2006).
5. Sadikot RT., et al.
DECLARATION OF CONFORMITY Benchmark MyBlock Digital Drybath
010:92
EN 55011:98/A1:99/A2:02
EN 61000-3-2:00+A2:05
EN 61000-3-3:95+A1:01+A2:05
EN 61000-4-2:95 +A1:98 +A2:01
EN 61000-4-3:02 +A1:02
EN 61000-4-4:04
DECLARATION OF CONFORMITY -Benchmark MultiTherm Shaker
010:92
EN 55011:98/A1:99/A2:02
EN 61000-3-2:00+A2:05
EN 61000-3-3:95+A1:01+A2:05
EN 61000-4-2:95 +A1:98 +A2:01
EN 61000-4-3:02 +A1:02
EN 61000-4-4:04
Specialty Materials For Dental Applications Brochure
Inhibitor 150-76-5
2, 6-Di-tert-butyl-4-methylphenol Inhibitor 128-37-0
Platinum (0)-1, 3-divinyl-1, 1, 3,
3-tetramethyldisiloxane
complex solution
Catalyst;
hydrosilylation
68478-92-2
Triphenylphosphine
LABORATORY NOTEBOOK ISSUANCE PAGE
)
58
.6
93
63
.5
46
65
.3
8
10
6.
42
10
7.
87
11
2.
41
19
5.
08
19
6.
97
20
0.
59
(2
81
)
(2
80
)
(2
85
Lab Notebook Guidelines
)
58
.6
93
63
.5
46
65
.3
8
10
6.
42
10
7.
87
11
2.
41
19
5.
08
19
6.
97
20
0.
59
(2
81
)
(2
80
)
(2
85
LABORATORY NOTEBOOK ISSUANCE PAGE
)
58
.6
93
63
.5
46
65
.3
8
10
6.
42
10
7.
87
11
2.
41
19
5.
08
19
6.
97
20
0.
59
(2
81
)
(2
80
)
(2
85
LABORATORY NOTEBOOK ISSUANCE PAGE
)
58
.6
93
63
.5
46
65
.3
8
10
6.
42
10
7.
87
11
2.
41
19
5.
08
19
6.
97
20
0.
59
(2
81
)
(2
80
)
(2
85
Data Sheet - 78830
faint yellow powder
Molecular weight: 174.2 g/mol
Molecular Formula: C7H7FO2S
Melting Point: 92-93°C
Store at room temperature
PMSF is an inhibitor of serine proteases and acetylcholinesterase
Protocol- EZHS100B-33K
4
0 14.8 - -
25 40 36.5 92
74 89 86.2 97
222 237 236.8 100
5
0 11 - -
25 36 34 94
Data Sheet - M7931
Acad. Sci. USA, 93, 9997
(1996).
4. Romanowski, P., et al., Proc. Natl. Acad. Sci. USA,
93, 10189 (1996).
5. Dalton, S., and Whitbread, L., Proc. Natl. Acad. Sci.
USA, 92, 2514 (1995).
6
Data Sheet - N9161
, et al., Proc. Natl. Acad. Sci. USA,
93, 13014-13019 (1996).
5. Huppert, S.S., et al., Nature, 405, 966-970
(2000).
6. Milner, L.A., et al., Blood, 93, 243-248 (1999).
Spare parts for Mobius®Bioreactors (50 L, 200 L, 1000 L & 2000 L)
applicable to any
14xYy valve
Cap Included
—Not Shown
92 or 93
(depending on
configuration)
Nipple
Only
52
86
1
5
76
50
97
96 87
94
95
Protocol: Mouse Lipocalin-2/NGAL
27.95 89%
62.5 62.5 57.54 92%
125 125.0 115.74 93%
3 31.25 35.4 33.06 93%
62.5 66.7 60.85 91%
125 129.2 102.37 79%
4
Quality Control Range Sheet- A60MG-104 and A60MG-204
1 22 - 46 pg/mL IL-18 Control1 17 – 36 pg/ml
Control 2 109 - 227 pg/mL Control 2 92 - 192 pg/ml
IL-5 Control 1 25
Application Note - Detection and quantification of leached Protein A from Eshmuno A resin using Cygnus F400 Protein A ELISA kit
0.102
1.334
1.29 95% 2.0
0.105 1.252
1 40
93% 92% 1.9
0.047 0.624
Day Dilution Result (ng/mL)
Average
Result
Verfication summary-03-0202-00
HMN713786
3 MRD (1:4) 35.58 1.0 3% 142.31 4.2 3% -
3 1:8 16.42 0.9 5% 131.35 6.9 5% 92%
3 1:16 8.17 0.4 5% 130.65 6.1 5% 92%
3 1:32 4.69 0.2 4% 150.01 5.8 4% 105%
Verfication summary-03-0202-00
HMN713786
3 MRD (1:4) 35.58 1.0 3% 142.31 4.2 3% -
3 1:8 16.42 0.9 5% 131.35 6.9 5% 92%
3 1:16 8.17 0.4 5% 130.65 6.1 5% 92%
3 1:32 4.69 0.2 4% 150.01 5.8 4% 105%
SARS-Cov2 anti-RBD IgG ELISA
14.0 13.5 96%
25 7.0 6.4 92%
12.5 3.5 3.2 92%
4 100 27.2 27.2
50 13.6 12.6
1/15